CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
1.540
+0.060 (4.05%)
At close: May 29, 2026, 4:00 PM EDT
1.540
0.00 (0.00%)
After-hours: May 29, 2026, 5:02 PM EDT
CEL-SCI Market Cap
CEL-SCI has a market cap or net worth of $22.32 million as of May 29, 2026. Its market cap has increased by 11.59% in one year.
Market Cap
22.32M
Enterprise Value
28.93M
1-Year Change
11.59%
Ranking
Category
Stock Price
$1.54
Market Cap Chart
Since December 1, 1998, CEL-SCI's market cap has decreased from $27.40M to $22.32M, a decrease of -18.54%. That is a compound annual growth rate of -0.74%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 28, 2026 | 12.60M | -71.49% |
| Dec 31, 2025 | 44.20M | 79.67% |
| Dec 31, 2024 | 24.60M | -81.90% |
| Dec 29, 2023 | 135.90M | 32.46% |
| Dec 30, 2022 | 102.60M | -66.58% |
| Dec 31, 2021 | 307.00M | -33.78% |
| Dec 31, 2020 | 463.60M | 43.22% |
| Dec 31, 2019 | 323.70M | 297.18% |
| Dec 31, 2018 | 81.50M | 226.00% |
| Dec 29, 2017 | 25.00M | 96.85% |
| Dec 30, 2016 | 12.70M | -73.60% |
| Dec 31, 2015 | 48.10M | -9.42% |
| Dec 31, 2014 | 53.10M | 80.61% |
| Dec 31, 2013 | 29.40M | -60.16% |
| Dec 31, 2012 | 73.80M | 10.81% |
| Dec 30, 2011 | 66.60M | -60.45% |
| Dec 31, 2010 | 168.40M | 25.11% |
| Dec 31, 2009 | 134.60M | 300.60% |
| Dec 31, 2008 | 33.60M | -42.37% |
| Dec 31, 2007 | 58.30M | 27.85% |
| Dec 29, 2006 | 45.60M | 25.27% |
| Dec 30, 2005 | 36.40M | -15.74% |
| Dec 31, 2004 | 43.20M | -37.39% |
| Dec 31, 2003 | 69.00M | 845.21% |
| Dec 31, 2002 | 7.30M | -67.12% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Genenta Science | 24.30M |
| Pasithea Therapeutics | 23.90M |
| Jasper Therapeutics | 23.21M |
| VYNE Therapeutics | 22.85M |
| Curis | 22.67M |
| Longeveron | 22.61M |
| NextCure | 22.37M |
| Traws Pharma | 22.12M |